<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475435</url>
  </required_header>
  <id_info>
    <org_study_id>DMSAL2712</org_study_id>
    <nct_id>NCT01475435</nct_id>
  </id_info>
  <brief_title>Oxidative Stress Markers Evaluation Before and After Periodontal Treatment of Diabetics Type 2 Patients</brief_title>
  <official_title>Oxidative Stress Markers Evaluation Before and After Periodontal Treatment of Diabetics Type 2 Patients With Generalized Chronic Periodontitis and Healthy Periodontium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abstract Diabetes mellitus and periodontal diseases are both chronic inflammatory disorders&#xD;
      that have a major impact on the health and well being of millions of individuals worldwide.&#xD;
      Periodontal diseases are among the most common diseases in humans, therefore, if the presence&#xD;
      of periodontal diseases plays any role in overall systemic health, the public health impact&#xD;
      may be substantial. An important factor that can be involved in the progression of the&#xD;
      periodontal disease is the production of Reactive Oxygen Species (ROS). The imbalance between&#xD;
      oxidative stress induced by ROS and the concentrations (or activity) of the antioxidant may&#xD;
      result in tissue damage. The ROS induce the activity of lipid peroxidation-Tbars,&#xD;
      myeloperoxidase (MPO), peroxidase and arginase, whose mechanisms reflect the severity of the&#xD;
      periodontal disease and it may offer the basis for a patient specific diagnostic test for&#xD;
      periodontitis and could have therapeutic significance. The aim of this study is to&#xD;
      investigate quantitatively the levels of oxidative stress markers (Myeloperoxidase,&#xD;
      Peroxidase, Lipid Peroxidation and Arginase) in saliva and in gingival crevicular fluid (GCF)&#xD;
      of diabetes type 2 subjects with generalized chronic periodontitis and periodontally healthy&#xD;
      individuals, and systematically healthy individuals with generalized chronic periodontitis&#xD;
      and periodontally healthy individuals, before and after periodontal treatment. Unstimulated&#xD;
      whole saliva will be collected for 5 min as well as GCF of 25 diabetes type 2 with&#xD;
      generalized chronic periodontitis, 25 diabetes type 2 periodontally healthy individuals as&#xD;
      controls, 25 systematically healthy individuals with generalized chronic periodontitis and 25&#xD;
      periodontally healthy individuals before and after treatment. The following clinical&#xD;
      parameters will be evaluated: probing pocket depth, probing attachment level, plaque index&#xD;
      and the gingival index. The activity of stress markers in saliva and GFC will be analyzed by&#xD;
      spectrophotometry. Adequate statistical analysis will be carried out with a p-value set at p&#xD;
      &lt; 0.05.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate level change of oxidative stress biomarkers in crevicular gingival fluid and whole saliva on diabetes type 2 individuals</measure>
    <time_frame>baseline and 4 weeks after periodontal treatment</time_frame>
    <description>The participants will be followed for an expected average of 4 weeks after periodontal treatment. The samples of saliva and crevicular gingival fluid will be evaluated at baseline and four weeks after periodontal treatment.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>chronic periodontitis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saliva and GCF samples will be evaluated before and after treatment from patients treated of chronic periodontitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>periodontally healthy individuals</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saliva and GCF samples will be evaluated from periodontally healthy individuals at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic periodontitis with diabetes type 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saliva and GCF samples will be evaluated before and after treatment from patients with diabetes type 2 treated of chronic periodontitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>periodontally healthy individuals with diabetes type 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saliva and GCF samples will be evaluated from periodontally healthy individuals with diabetes type 2 at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>non- surgical periodontal treatment</intervention_name>
    <description>scaling and root planning</description>
    <arm_group_label>chronic periodontitis</arm_group_label>
    <arm_group_label>chronic periodontitis with diabetes type 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prophylaxis</intervention_name>
    <description>Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.</description>
    <arm_group_label>periodontally healthy individuals</arm_group_label>
    <arm_group_label>periodontally healthy individuals with diabetes type 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes and chronic periodontitis(more than 30% of the sites&#xD;
             involved, AAP, 1999)&#xD;
&#xD;
          -  Patients with type 2 diabetes and periodontally healthy (AAP, 1999)&#xD;
&#xD;
          -  Patients systemically healthy with chronic periodontitis (more than 30% of the sites&#xD;
             involved)&#xD;
&#xD;
          -  Patients systemically and periodontally healthy&#xD;
&#xD;
          -  Patients with at least 15 natural teeth (excluding 3rd molars).&#xD;
&#xD;
          -  At least 30% of sites with probing pocket depth (PD)&gt; 5 mm and a maximum of 60% sites&#xD;
             with PS &lt;7 mm&#xD;
&#xD;
          -  Clinical attachment level (CAL)&gt; 4 mm&#xD;
&#xD;
          -  Visible plaque and bleeding on probing (BOP)&#xD;
&#xD;
          -  Patients with type 2 diabetes have to bear the disease for at least five years and&#xD;
             have to show a blood percentage of glycated hemoglobin between 6.5% to 8% (UKPDS 1998)&#xD;
             at baseline&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Individuals with periodontal pockets deeper than 7 mm&#xD;
&#xD;
          -  Patients with any other systemic disease (except diabetes type 2)&#xD;
&#xD;
          -  Patients who have used medications such as anticoagulants, contraceptives or&#xD;
             antidepressants in the past 6 months&#xD;
&#xD;
          -  Patients who have used antibiotic and anti-inflammatory drugs in the last 3 months&#xD;
             before the of the study&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients who have received periodontal treatment in the last six months before the&#xD;
             start of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luiz A Lima, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luiz Antônio Pugliesi Alves de Lima, PhD</last_name>
    <phone>55-11-30917833</phone>
    <email>lapalima@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Paula Sassá Benedete</last_name>
    <phone>55-11-30917833</phone>
    <email>abenedete@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05508-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz Antônio Pugliesi Alves de Lima, PhD</last_name>
      <phone>55-11-30917833</phone>
      <email>lapalima@usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Ana Paula Sassá Benedete</last_name>
      <phone>55-11-30917833</phone>
      <email>abenedete@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>August 22, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2011</study_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Luiz Antonio Pugliesi Alves de Lima</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

